YARGESA, also known by its generic name miglustat, is a medication primarily used in the treatment of type 1 Gaucher disease, a rare genetic disorder characterized by the accumulation of glucocerebroside in cells, leading to symptoms such as enlargement of the liver and spleen, anemia, bone diseases, and fatigue. YARGESA works by inhibiting the enzyme glucosylceramide synthase, which is involved in the synthesis of glucocerebroside, thereby reducing its accumulation in the body. It is an oral medication, offering an alternative to enzyme replacement therapies for patients who are unable or unwilling to receive intravenous treatments. YARGESA is also explored for its potential use in treating other conditions, including Niemann-Pick disease type C and certain glycosphingolipid storage disorders, highlighting its importance in the field of rare genetic diseases.